K. H. Park

TL;DR: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease‐free survival and overall survival among patients with HER2‐negative breast cancer who had residual invasive disease on pathological testing.

TL;DR: In this paper, a phase II neoadjuvant trial evaluated bevacizumab, docetaxel and carboplatin in triple-negative breast cancer, and the primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN).

TL;DR: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

TL;DR: The safety profile of H-SC was comparable to that ofH-IV, and the imbalance was largely driven by increased reporting of SAEs in the “infections” disease category in the SC v the IV arm.

TL;DR: It is confirmed that the T1-2 team will not be competing in the Eurovision Song Contest this year because of a conflict of interest.